Stem Cell Medicine
Stem Cell Therapeutic Technology
Company Overview
Snapshot
Founded in March 2010 by Ehud Marom, Stem Cell Medicine operates with 11–50 employees and has raised $5.5M across two funding rounds. In March 2019, the company secured a significant grant from The Israeli Ministry of Economy.
Business overview
Stem Cell Medicine is a biotechnology company focused on developing second-generation cell therapy products. These products are designed as stand-alone treatments or in combination with pharmaceuticals, primarily targeting neurological indications such as multiple sclerosis, pain, and neuromuscular injuries. The company manages the production, registration, and marketing of its products, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Strategic signal
In January 2019, Stem Cell Medicine licensed exosome technology for treating autism from Ramot at Tel Aviv University. This strategic move signals the company's commitment to expanding its therapeutic pipeline into new neurological conditions, leveraging advanced cell-based technologies to address unmet medical needs and potentially opening new market opportunities in autism treatment.
Company Intelligence Q&A
- When was Stem Cell Medicine founded?
- Stem Cell Medicine was founded in March 2010 by Ehud Marom.
- What is Stem Cell Medicine's primary focus?
- Stem Cell Medicine focuses on developing second-generation cell therapy products for neurological indications such as multiple sclerosis, pain, and neuromuscular injuries.
- What was a significant licensing agreement for Stem Cell Medicine?
- In January 2019, Stem Cell Medicine licensed exosome technology for treating autism from Ramot at Tel Aviv University.
- Which entity provided a grant to Stem Cell Medicine?
- In March 2019, The Israeli Ministry of Economy provided a grant of $5.5M to Stem Cell Medicine.
- What type of technology did Stem Cell Medicine highlight in April 2018?
- In April 2018, Stem Cell Medicine highlighted human muscle progenitor cells ectopically expressing neurotrophic factors to enhance intrinsic neuronal regeneration.